Recall Weekly
Moderate riskFDA DrugClass II

New Life Pharma Tirzepatide injection recalled for sterility concerns

New Life Pharma LLC is recalling Tirzepatide 10mg multi-dose vials (Lot 240709, expiration 7/31/2026) because the manufacturer cannot confirm the product is sterile. The vials were distributed in Ohio. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have Tirzepatide from New Life Pharma with Lot 240709
  2. Do not use the recalled vials
  3. Contact your pharmacy or healthcare provider for a replacement or alternative
Official notice ↗

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03.
Sold in
OH
Made for
Adults (0 months and older)

This recall covers 4 products — see all of them.

Details

Units affected
23 vials
Illnesses reported
None reported
Manufactured in
265 Livingston St, N/A, Northvale, NJ, United States
Classification
Class II
Recall number
D-0394-2026

In the FDA's words

Description
Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03. Lack of Assurance of Sterility Lot 240709, exp 7/31/2026 Distribution: OH Affected quantity: 23 vials
Hazard
Lack of Assurance of Sterility

4 products in this recall

Nomida semaglutide and tirzepatide vials recalled for sterility concerns

New Life Pharma is recalling four sterile multi-dose vials of semaglutide and tirzepatide injection, all sold under the Nomida name, because the company cannot assure they are sterile. The recall covers 2 mg and 10 mg semaglutide vials and 10 mg and 15 mg tirzepatide vials, and the products were distributed in Ohio. No injuries have been reported.

The agency lists each product separately. Check every one you might have.

Related topics

SterilityDrugsOHMore from FDA Drug